AI Insight: Avanos Medical trades 47% above its high-confidence fair value estimate of $13.18, indicating potential overvaluation despite no downside risk in Monte Carlo scenarios. DCF suggests deep undervaluation (-$17.01 mid), but price/sales and analyst targets imply a mixed outlook. Financials reveal strong liquidity and leverage, but zero profitability and efficiency raise risk concerns.